Protagonist posts Q2 2026 profit as ICOTYDE launch and rusfertide review advance
Protagonist reported $162.8 million net income for the quarter, driven by Takeda payments, while awaiting an FDA decision on rusfertide in August 2026.
SEC filing
Latest
1 story